Skip to content
2000
image of Effect of Wuzhi Capsule (WZC) on the Pharmacokinetics of Tacrolimus in Renal Transplantation Recipients

Abstract

Background

Previous studies have shown that WZC can increase tacrolimus blood concentration when co-administered. However, limited knowledge exists regarding the pharmacokinetics of both tacrolimus and the bioactive lignans in WZC when administered simultaneously in renal transplantation patients.

Aims

This study aimed to investigate the pharmacokinetics of tacrolimus and multiple bioactive lignans in capsule (WZC) when co-administered with 5 bioactive components in renal transplantation recipients.

Objective

The objective of this study was to develop a method for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC using liquid-liquid extraction followed by LC-MS/MS analysis.

Methods

A liquid-liquid extraction method combined with LC-MS/MS analysis was developed for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC. Human whole blood samples were analyzed, and the accuracy and precision of the method were evaluated.

Results

The developed method showed good linearity and accuracy for the quantification of tacrolimus and bioactive lignans in WZC. Pharmacokinetic analysis revealed significant effects of WZC co-administration on both V/F and CL/F in renal transplantation patients.

Conclusion

This study demonstrated that simultaneous administration of WZC had notable effects on the pharmacokinetics of tacrolimus and bioactive lignans in renal transplantation patients. The developed method proved to be reliable and sensitive for determining the whole blood concentrations of tacrolimus and WZC, making it suitable for pharmacokinetic studies in transplant patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002320686250310054152
2025-03-19
2025-09-05

  • From This Site

    /content/journals/cdm/10.2174/0113892002320686250310054152
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Christians U. Jacobsen W. Benet L.Z. Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 2002 41 11 813 851 10.2165/00003088‑200241110‑00003 12190331
    [Google Scholar]
  2. Staatz C.E. Tett S.E. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin. Pharmacokinet. 2015 54 10 993 1025 10.1007/s40262‑015‑0282‑2 26038096
    [Google Scholar]
  3. Hendrickson R.J. Karrer F.M. Wachs M.E. Slater K. Bak T.E. Kam I. Pediatric liver transplantation. Curr. Opin. Pediatr. 2004 16 3 309 313 10.1097/01.mop.0000127160.82531.77 15167019
    [Google Scholar]
  4. Kelly D. Jara P. Rodeck B. Lykavieris P. Burdelski M. Becker M. Gridelli B. Boillot O. Manzanares J. Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial. Lancet 2004 364 9439 1054 1061 10.1016/S0140‑6736(04)17060‑8 15380964
    [Google Scholar]
  5. Li L. Li C.J. Tacrolimus in preventing transplant rejection in Chinese patients – optimizing use. Drug Des. Devel. Ther. 2015 9 473 485 10.2147/DDDT.S41349 25609922
    [Google Scholar]
  6. Schutte-Nutgen K. Tholking G. Suwelack B. Reuter S. Tacrolimus - Pharmacokinetic considerations for clinicians. Curr. Drug Metab. 2018 19 4 342 350 10.2174/1389200219666180101104159 29298646
    [Google Scholar]
  7. Chen X. Wang D.D. Xu H. Li Z.P. Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: Initial dose recommendation. Transl. Pediatr. 2020 9 5 576 586 10.21037/tp‑20‑84 33209719
    [Google Scholar]
  8. Qin X.L. Bi H.C. Wang X.D. Li J.L. Wang Y. Xue X.P. Chen X. Wang C.X. Xu L.J. Wang Y.T. Huang M. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int. J. Pharm. 2010 389 1-2 114 121 10.1016/j.ijpharm.2010.01.025 20097278
    [Google Scholar]
  9. Qin X.L. Yu T. Li L.J. Wang Y. Gu H.M. Wang Y.T. Huang M. Bi H.C. Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. Phytomedicine 2013 20 3-4 375 379 10.1016/j.phymed.2012.11.008 23267661
    [Google Scholar]
  10. Bowman L.J. Brennan D.C. The role of tacrolimus in renal transplantation. Expert Opin. Pharmacother. 2008 9 4 635 643 10.1517/14656566.9.4.635 18312164
    [Google Scholar]
  11. Wei H. Tao X. Di P. Yang Y. Li J. Qian X. Feng J. Chen W. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab. Dispos. 2013 41 7 1398 1403 10.1124/dmd.112.050302 23628674
    [Google Scholar]
  12. Chen Z. Liu F. Zheng N. Guo M. Bao L. Zhan Y. Zhang M. Zhao Y. Guo W. Ding G. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. Biomed. Pharmacother. 2019 110 285 293 10.1016/j.biopha.2018.11.069 30522014
    [Google Scholar]
  13. Qu J. Bian R. Liu B. Chen J. Zhai J. Teng F. Guo W. Wei H. The pharmacokinetic study of tacrolimus and Wuzhi capsule in Chinese liver transplant patients. Front. Pharmacol. 2022 13 956166 10.3389/fphar.2022.956166 36188616
    [Google Scholar]
  14. Qin X. Chen X. Zhong G. Fan X. Wang Y. Xue X. Wang Y. Huang M. Bi H. Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp. Phytomedicine 2014 21 5 766 772 10.1016/j.phymed.2013.12.006 24462213
    [Google Scholar]
  15. Jiang W. Wang X. Xu X. Kong L. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int. J. Clin. Pharmacol. Ther. 2010 48 3 224 229 10.5414/CPP48224 20197017
    [Google Scholar]
  16. Qin X.L. Chen X. Wang Y. Xue X.P. Wang Y. Li J.L. Wang X.D. Zhong G.P. Wang C.X. Yang H. Huang M. Bi H.C. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. Drug Metab. Dispos. 2014 42 1 193 199 10.1124/dmd.113.053892 24195812
    [Google Scholar]
  17. Xin H.W. Li Q. Wu X.C. He Y. Yu A.R. Xiong L. Xiong Y. Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients. Eur. J. Clin. Pharmacol. 2011 67 12 1309 1311 10.1007/s00228‑011‑1075‑7 21656210
    [Google Scholar]
  18. Xin H.W. Wu X.C. Li Q. Yu A.R. Zhu M. Shen Y. Su D. Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br. J. Clin. Pharmacol. 2007 64 4 469 475 10.1111/j.1365‑2125.2007.02922.x 17506780
    [Google Scholar]
  19. Wei H. Miao H. Yun Y. Li J. Qian X. Wu R. Chen W. Validation of an LC-MS/MS method for quantitative analysis of the 5 bioactive components of Wuzhi capsule in human plasma samples. Ther. Drug Monit. 2014 36 6 781 788 10.1097/FTD.0000000000000079 25392942
    [Google Scholar]
  20. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD., Guidance for Industry: Bioanalytical Method Validation, FDA. 2013 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry (Accessed on: April 26, 2021).
  21. Staatz C.E. Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 2004 43 10 623 653 10.2165/00003088‑200443100‑00001 15244495
    [Google Scholar]
  22. Zhang C. Ren X. Liu Y. Huang L. Feng Y. Zhang X. Effects of wuzhi capsule on whole-blood tacrolimus concentration levels: A systematic review and meta-analysis. Ther. Drug Monit. 2024 46 1 33 41 10.1097/FTD.0000000000001155 38150711
    [Google Scholar]
  23. Cheng F. Li Q. Wang J. Zeng F. Zhang Y. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. J. Clin. Pharm. Ther. 2021 46 6 1636 1649 10.1111/jcpt.13493 34342024
    [Google Scholar]
  24. He Q. Bu F. Wang Q. Li M. Lin J. Tang Z. Mak W.Y. Zhuang X. Zhu X. Lin H.S. Xiang X. Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A physiologically based pharmacokinetic modeling approach. Int. J. Mol. Sci. 2022 23 9 4485 10.3390/ijms23094485 35562875
    [Google Scholar]
  25. Teng F. Wang W. Zhang W. Qu J. Liu B. Chen J. Liu S. Li M. Chen W. Wei H. Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers. Biopharm. Drug Dispos. 2022 43 4 119 129 10.1002/bdd.2312 35180322
    [Google Scholar]
  26. Yan L. Yang Z.Q. Shi Y.Y. Ren J. Yang C.L. Wan Z.L. Bai Y.J. Luo L.M. Wang L.L. Li Y. Effects of wuzhi capsules on blood concentration of tacrolimus in renal transplant recipients. Ann. Transplant. 2019 24 594 604 10.12659/AOT.918980 31712547
    [Google Scholar]
  27. Zhang S.F. Tang B.H. Wei A. Du Y. Guan Z.W. Li Y. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes. Xenobiotica 2022 52 3 312 321 10.1080/00498254.2022.2064252 35395919
    [Google Scholar]
  28. Huang S. Song W. Jiang S. Li Y. Wang M. Yang N. Zhu H. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction. Chem. Biol. Interact. 2024 391 110906 10.1016/j.cbi.2024.110906 38340974
    [Google Scholar]
  29. Zhang H. Bu F. Li L. Jiao Z. Ma G. Cai W. Zhuang X. Lin H.S. Shin J.G. Xiang X. Prediction of Drug–Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically‐Based Pharmacokinetic Modelling. Basic Clin. Pharmacol. Toxicol. 2018 122 3 331 340 10.1111/bcpt.12914 28945011
    [Google Scholar]
  30. He Q. Bu F. Zhang H. Wang Q. Tang Z. Yuan J. Lin H.S. Xiang X. Investigation of the impact of CYP3A5 polymorphism on drug–drug interaction between tacrolimus and schisantherin a/schisandrin a based on physiologically-based pharmacokinetic modeling. Pharmaceuticals (Basel) 2021 14 3 198 10.3390/ph14030198 33673653
    [Google Scholar]
  31. Seo H.J. Ji S.B. Kim S.E. Lee G.M. Park S.Y. Wu Z. Jang D.S. Liu K.H. Inhibitory effects of Schisandra lignans on cytochrome P450s and uridine 5′-diphospho-glucuronosyl transferases in human liver microsomes. Pharmaceutics 2021 13 3 371 10.3390/pharmaceutics13030371 33802239
    [Google Scholar]
/content/journals/cdm/10.2174/0113892002320686250310054152
Loading
Effect of Wuzhi Capsule (WZC) on the Pharmacokinetics of Tacrolimus in Renal Transplantation Recipients
Bentham Science Publishers ; https://doi.org/10.2174/0113892002320686250310054152
/content/journals/cdm/10.2174/0113892002320686250310054152
/content/journals/cdm/10.2174/0113892002320686250310054152
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: renal transplantation ; pharmacokinetics ; tacrolimus ; LC-MS/MS ; Wuzhi capsule

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test